Relationship of Cerebral Perfusion Pressure Variability to Sepsis-associated Encephalopathy

October 31, 2017 updated by: Kang Yan
The purpose of the study is to evaluate whether variability of CPP (cerebral perfusion pressure) is related to sepsis-associated encephalopathy and outcomes of patients with sepsis.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Encephalopathy is a common complication of sepsis, impaired cerebrovascular autoregulation (AR) in patients with sepsis is considered related to Sepsis-associated encephalopathy (SAE). As AR is important in stabilizing the cerebral perfusion pressure, whether greater variability of CPP is related to SAE and mortality or not remains unclear. We conduct this study to evaluate the relationship between them.

Study Type

Observational

Enrollment (Actual)

110

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • Kang Yan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

all patients admit to the general ICU of an academic teaching hospital

Description

Inclusion Criteria:

  • clinical symptoms of sepsis, severe sepsis and septic shock
  • age over 18 years

Exclusion Criteria:

  • preexisting Neurological diseases
  • traumatic brain injury
  • intracranial infectious disease
  • severe hepatic or renal dysfunction
  • ICU discharge Within 72 hours
  • pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
SAE
patient who develop encephalopathy in the progress of sepsis
non-SAE
patient who do not develop encephalopathy in the progress of sepsis

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
relationship between cerebral perfusion pressure variability and sepsis-associated encephalopathy
Time Frame: cerebral perfusion pressure is assessed up to 72 hours
To estimate CPP noninvasively, we will monitor the middle cerebral artery flow velocity of patients with sepsis using transcranial Doppler ultrasound in the first 72h of their enrollment. Diagnosis of a SAE was performed using the confusion assessment method for ICU(CAM-ICU).
cerebral perfusion pressure is assessed up to 72 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Duration of mechanical ventilation
Time Frame: All the participants will be followed up until discharge or death, assessed up to 24 months
All the participants will be followed up until discharge or death, assessed up to 24 months
Time of ICU stay
Time Frame: All the participants will be followed up until discharge or death, assessed up to 24 months
All the participants will be followed up until discharge or death, assessed up to 24 months
Time of hospital stay
Time Frame: All the participants will be followed up until discharge or death, assessed up to 24 months
All the participants will be followed up until discharge or death, assessed up to 24 months
90-day mortality rate
Time Frame: All the participants will be followed up until 90 days after their enrollment or death
All the participants will be followed up until 90 days after their enrollment or death
1-year mortality rate
Time Frame: All the participants will be followed up until 1 year after their enrollment or death
All the participants will be followed up until 1 year after their enrollment or death
2-year mortality rate
Time Frame: All the participants will be followed up until 2 years after their enrollment or death
All the participants will be followed up until 2 years after their enrollment or death
1-year quality of life of survivors
Time Frame: All the participants will be followed up until 1 year after their enrollment or death
EQ-5D will be used to evaluate quality of life of survivors
All the participants will be followed up until 1 year after their enrollment or death
2-year quality of life of survivors
Time Frame: All the participants will be followed up until 2 year after their enrollment or death
EQ-5D will be used to evaluate quality of life of survivors
All the participants will be followed up until 2 year after their enrollment or death

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2014

Primary Completion (Actual)

March 1, 2015

Study Completion (Actual)

March 1, 2017

Study Registration Dates

First Submitted

October 27, 2014

First Submitted That Met QC Criteria

November 6, 2014

First Posted (Estimate)

November 11, 2014

Study Record Updates

Last Update Posted (Actual)

November 6, 2017

Last Update Submitted That Met QC Criteria

October 31, 2017

Last Verified

October 1, 2017

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sepsis

Clinical Trials on no interventions

Subscribe